Literature DB >> 25983000

Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells.

Jing Liu1, Jin Lin1, Lin-Feng Huang1, Bo Huang1, Yan-Mei Xu1, Jing Li2, Yan Wang1, Jing Zhang1, Wei-Ming Yang1, Qing-Hua Min1, Xiao-Zhong Wang3.   

Abstract

Cancer progression often involves the disorder of the cell cycle, and a number of effective chemotherapeutic drugs have been shown to induce cell cycle arrest. The purpose of this study was to comprehensively investigate the effects of imatinib on the expression profile of cell cycle genes in the chronic myeloid leukemia (CML) K562 cell line. In addition, we also investigated alternative splicing of the cell cycle genes affected by imatinib, since an important relationship has been shown to exist between RNA splicing and cell cycle progression. Exon array analysis was performed using total RNA purified from normal and imatinib-treated K562 cells. We identified 185 differentially expressed genes and 277 alternative splicing events between the two cell groups. A detailed analysis by reverse transcription-PCR (RT-PCR) of key genes confirmed the experimental results of the exon array. These results suggested that treatment of K562 cells with imatinib shifts the expression and alternative splicing profiles of several cell cycle-related genes. Importantly, these findings may help improve imatinib treatment strategies in patients with CML and may be useful for imatinib resistance research and CML drug development.

Entities:  

Keywords:  Alternative splicing; Cell cycle; Chronic myeloid leukemia; Gene expression profile; Imatinib; K562

Mesh:

Substances:

Year:  2015        PMID: 25983000     DOI: 10.1007/s13277-015-3493-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Aberrant expression of splicing factors in newly diagnosed acute myeloid leukemia.

Authors:  Jing Liu; Bo Huang; Yun Xiao; Huo-Mei Xiong; Jing Li; Dan-Qin Feng; Xi-Min Chen; Hai-Bin Zhang; Xiao-Zhong Wang
Journal:  Onkologie       Date:  2012-05-22

Review 2.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

Review 3.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

4.  Removal of a single alpha-tubulin gene intron suppresses cell cycle arrest phenotypes of splicing factor mutations in Saccharomyces cerevisiae.

Authors:  C Geoffrey Burns; Ryoma Ohi; Sapna Mehta; Eileen T O'Toole; Mark Winey; Tyson A Clark; Charles W Sugnet; Manuel Ares; Kathleen L Gould
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

5.  Alternative splicing of SYK regulates mitosis and cell survival.

Authors:  Panagiotis Prinos; Daniel Garneau; Jean-François Lucier; Daniel Gendron; Sonia Couture; Marianne Boivin; Jean-Philippe Brosseau; Elvy Lapointe; Philippe Thibault; Mathieu Durand; Karine Tremblay; Julien Gervais-Bird; Hanad Nwilati; Roscoe Klinck; Benoit Chabot; Jean-Pierre Perreault; Raymund J Wellinger; Sherif Abou Elela
Journal:  Nat Struct Mol Biol       Date:  2011-05-08       Impact factor: 15.369

Review 6.  Complexities in the development of cyclin-dependent kinase inhibitor drugs.

Authors:  Edward A Sausville
Journal:  Trends Mol Med       Date:  2002       Impact factor: 11.951

7.  Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells.

Authors:  Ireneusz Majsterek; Michal Arabski; Agnieszka Czechowska; Dariusz Pytel; Zbigniew Morawiec; Alina Morawiec-Bajda; Janusz Blasiak
Journal:  Z Naturforsch C J Biosci       Date:  2006 Nov-Dec

8.  Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c.

Authors:  Noriko Nishimura; Yusuke Furukawa; Krittaya Sutheesophon; Mitsuru Nakamura; Kenji Kishi; Keiko Okuda; Yuko Sato; Yasuhiko Kano
Journal:  Oncogene       Date:  2003-06-26       Impact factor: 9.867

9.  Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells.

Authors:  Jan-Gowth Chang; Den-Mei Yang; Wen-Hsin Chang; Lu-Ping Chow; Wen-Ling Chan; Hui-Hua Lin; Hsien-Da Huang; Ya-Sian Chang; Cheng-Hao Hung; Wen-Kuang Yang
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

10.  Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development.

Authors:  S Senese; Y C Lo; D Huang; T A Zangle; A A Gholkar; L Robert; B Homet; A Ribas; M K Summers; M A Teitell; R Damoiseaux; J Z Torres
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.